596 related articles for article (PubMed ID: 34707380)
1. Emerging Carbapenem-Resistant
Tilahun M; Kassa Y; Gedefie A; Ashagire M
Infect Drug Resist; 2021; 14():4363-4374. PubMed ID: 34707380
[TBL] [Abstract][Full Text] [Related]
2. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
[TBL] [Abstract][Full Text] [Related]
3. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.
Rodríguez-Baño J; Gutiérrez-Gutiérrez B; Machuca I; Pascual A
Clin Microbiol Rev; 2018 Apr; 31(2):. PubMed ID: 29444952
[TBL] [Abstract][Full Text] [Related]
5. Infections Caused by Carbapenem-Resistant
Sheu CC; Chang YT; Lin SY; Chen YH; Hsueh PR
Front Microbiol; 2019; 10():80. PubMed ID: 30761114
[TBL] [Abstract][Full Text] [Related]
6. Present and Future of Carbapenem-resistant
Suay-García B; Pérez-Gracia MT
Antibiotics (Basel); 2019 Aug; 8(3):. PubMed ID: 31430964
[TBL] [Abstract][Full Text] [Related]
7. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.
Bader MS; Loeb M; Leto D; Brooks AA
Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743
[TBL] [Abstract][Full Text] [Related]
8. Genetic diversity and in vitro activity of ceftazidime/avibactam and aztreonam/avibactam against imipenem-resistant Enterobacteriaceae isolates in Southwest China: A single-centre study.
Wei J; Zou C; Wang D; Huang A; Niu S
J Glob Antimicrob Resist; 2020 Sep; 22():448-451. PubMed ID: 32387260
[TBL] [Abstract][Full Text] [Related]
9.
Kazmierczak KM; Bradford PA; Stone GG; de Jonge BLM; Sahm DF
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249690
[No Abstract] [Full Text] [Related]
10. Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens.
Karaiskos I; Galani I; Souli M; Giamarellou H
Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):133-149. PubMed ID: 30626244
[TBL] [Abstract][Full Text] [Related]
11. New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship.
Jean SS; Gould IM; Lee WS; Hsueh PR;
Drugs; 2019 May; 79(7):705-714. PubMed ID: 30972660
[TBL] [Abstract][Full Text] [Related]
12. Carbapenem-Resistant
Karampatakis T; Tsergouli K; Behzadi P
Antibiotics (Basel); 2023 Jan; 12(2):. PubMed ID: 36830145
[No Abstract] [Full Text] [Related]
13. Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae.
Haidar G; Clancy CJ; Chen L; Samanta P; Shields RK; Kreiswirth BN; Nguyen MH
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630202
[TBL] [Abstract][Full Text] [Related]
14. Emerging antibiotic resistance: carbapenemase-producing enterobacteria. Bad new bugs, still no new drugs.
Spera AM; Esposito S; Pagliano P
Infez Med; 2019 Dec; 27(4):357-364. PubMed ID: 31846984
[TBL] [Abstract][Full Text] [Related]
15. Carbapenem-Resistant Enterobacterales: Considerations for Treatment in the Era of New Antimicrobials and Evolving Enzymology.
Lasko MJ; Nicolau DP
Curr Infect Dis Rep; 2020 Feb; 22(3):6. PubMed ID: 32034524
[TBL] [Abstract][Full Text] [Related]
16. Cefiderocol, a Siderophore Cephalosporin, as a Treatment Option for Infections Caused by Carbapenem-Resistant Enterobacterales.
Kaye KS; Naas T; Pogue JM; Rossolini GM
Infect Dis Ther; 2023 Mar; 12(3):777-806. PubMed ID: 36847998
[TBL] [Abstract][Full Text] [Related]
17. In Vitro and In Vivo Evaluations of β-Lactam/β-Lactamase Mono- and Combined Therapies against Carbapenem-Nonsusceptible Enterobacteriaceae in Taiwan.
Yang TY; Hsieh YJ; Kao LT; Liu GH; Lian SH; Wang LC; Lin IL; Lin YT; Wang SF; Tseng SP; Lu PL
Microorganisms; 2020 Dec; 8(12):. PubMed ID: 33322803
[TBL] [Abstract][Full Text] [Related]
18. Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant
Ackley R; Roshdy D; Meredith J; Minor S; Anderson WE; Capraro GA; Polk C
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094128
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic and molecular characteristics of carbapenem-non-susceptible Enterobacteriaceae from a teaching hospital in Wenzhou, southern China.
Zhou T; Zhang X; Guo M; Ye J; Lu Y; Bao Q; Chi W
Jpn J Infect Dis; 2013; 66(2):96-102. PubMed ID: 23514904
[TBL] [Abstract][Full Text] [Related]
20. An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam.
Wenzler E; Scoble PJ
Infect Dis Ther; 2020 Dec; 9(4):769-784. PubMed ID: 33025557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
